RBC Capital Maintains Outperform on Ultragenyx Pharmaceutical, Raises Price Target to $40

RBC Capital analyst Luca Issi maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Outperform and raises the price target from $35 to $40.